Tags

Type your tag names separated by a space and hit enter

Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease.
J Clin Invest. 1997 Oct 01; 100(7):1847-52.JCI

Abstract

Intracellular polymerization and sickling depend markedly on the cellular concentration of sickle hemoglobin (Hb S). A possible therapeutic strategy for sickle cell disease is based on reducing the cellular concentration of Hb S through prevention of erythrocyte dehydration. The K-Cl cotransporter is a major determinant of sickle cell dehydration and is inhibited by increasing erythrocyte Mg content. We studied 10 patients with sickle cell disease before treatment and after 2 and 4 wk of treatment with oral Mg supplements (0.6 meq/kg/d Mg pidolate). Hematological parameters, erythrocyte Na, K, and Mg content, erythrocyte density, membrane transport of Na and K, and osmotic gradient ektacytometry were measured. We found significant increases in sickle erythrocyte Mg and K content and reduction in the number of dense sickle erythrocytes. Erythrocyte K-Cl cotransport was reduced significantly. We also observed a significant reduction in the absolute reticulocyte count and in the number of immature reticulocytes. Ektacytometric analysis showed changes indicative of improved hydration of the erythrocytes. There were no laboratory or clinical signs of hypermagnesemia. Mild, transient diarrhea was the only reported side effect. We conclude that oral Mg supplementation reduces the number of dense erythrocytes and improves the erythrocyte membrane transport abnormalities of patients with sickle cell disease.

Links

PMC Free PDF
PMC Free Full Text
Aggregator Full Text

Authors+Show Affiliations

De Franceschi L
Department of Medicine, University of Verona, Verona, 37134 Italy.
Bachir D
No affiliation info available
Galacteros F
No affiliation info available
Tchernia G
No affiliation info available
Cynober T
No affiliation info available
Alper S
No affiliation info available
Platt O
No affiliation info available
Beuzard Y
No affiliation info available
Brugnara C
No affiliation info available

MeSH

AdolescentAdultAnemia, Sickle CellBiological TransportDietary SupplementsErythrocyte DeformabilityErythrocytes, AbnormalFemaleHematologic TestsHumansMagnesiumMalePotassiumPyrrolidonecarboxylic AcidSodiumSodium-Potassium-Exchanging ATPaseWater-Electrolyte Balance

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

9312186

Citation

De Franceschi, L, et al. "Oral Magnesium Supplements Reduce Erythrocyte Dehydration in Patients With Sickle Cell Disease." The Journal of Clinical Investigation, vol. 100, no. 7, 1997, pp. 1847-52.
De Franceschi L, Bachir D, Galacteros F, et al. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. J Clin Invest. 1997;100(7):1847-52.
De Franceschi, L., Bachir, D., Galacteros, F., Tchernia, G., Cynober, T., Alper, S., Platt, O., Beuzard, Y., & Brugnara, C. (1997). Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. The Journal of Clinical Investigation, 100(7), 1847-52.
De Franceschi L, et al. Oral Magnesium Supplements Reduce Erythrocyte Dehydration in Patients With Sickle Cell Disease. J Clin Invest. 1997 Oct 1;100(7):1847-52. PubMed PMID: 9312186.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. AU - De Franceschi,L, AU - Bachir,D, AU - Galacteros,F, AU - Tchernia,G, AU - Cynober,T, AU - Alper,S, AU - Platt,O, AU - Beuzard,Y, AU - Brugnara,C, PY - 1997/10/6/pubmed PY - 1997/10/6/medline PY - 1997/10/6/entrez SP - 1847 EP - 52 JF - The Journal of clinical investigation JO - J Clin Invest VL - 100 IS - 7 N2 - Intracellular polymerization and sickling depend markedly on the cellular concentration of sickle hemoglobin (Hb S). A possible therapeutic strategy for sickle cell disease is based on reducing the cellular concentration of Hb S through prevention of erythrocyte dehydration. The K-Cl cotransporter is a major determinant of sickle cell dehydration and is inhibited by increasing erythrocyte Mg content. We studied 10 patients with sickle cell disease before treatment and after 2 and 4 wk of treatment with oral Mg supplements (0.6 meq/kg/d Mg pidolate). Hematological parameters, erythrocyte Na, K, and Mg content, erythrocyte density, membrane transport of Na and K, and osmotic gradient ektacytometry were measured. We found significant increases in sickle erythrocyte Mg and K content and reduction in the number of dense sickle erythrocytes. Erythrocyte K-Cl cotransport was reduced significantly. We also observed a significant reduction in the absolute reticulocyte count and in the number of immature reticulocytes. Ektacytometric analysis showed changes indicative of improved hydration of the erythrocytes. There were no laboratory or clinical signs of hypermagnesemia. Mild, transient diarrhea was the only reported side effect. We conclude that oral Mg supplementation reduces the number of dense erythrocytes and improves the erythrocyte membrane transport abnormalities of patients with sickle cell disease. SN - 0021-9738 UR - https://www.unboundmedicine.com/medline/citation/9312186/Oral_magnesium_supplements_reduce_erythrocyte_dehydration_in_patients_with_sickle_cell_disease_ L2 - https://doi.org/10.1172/JCI119713 DB - PRIME DP - Unbound Medicine ER -